Message from the Guest Editor

Dear Colleagues,

There is currently significant interest in the discovery and development of epigenetic drugs for many chronic diseases, including cancer, inflammatory, metabolic and neuro-psychiatric conditions. It is hypothesised that these may modify the transcription of many causative genes implicated in the development and maintenance of such diseases, and hence inhibitors of these proteins may deliver novel disease modifying therapeutics. There are questions, however, around the tolerability or therapeutic index of such agents. In this issue we will discuss the latest developments in both academia and industry.

Prof. Dr. Chas Bountra
Guest Editor

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: citations available in PubMed, full-text archived in PubMed Central. Covered by Embase and Scopus. To be indexed in the Emerging Sources Citation Index - ESCI (Web of Science) from Vol. 10 (2017).

CiteScore: 4.90, based on citations in 2016 to articles published 2013-2015,

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 27 days after submission; acceptance to publication is undertaken in 5 days (median values for papers published in this journal in first half of 2017).